ESR1 and breast cancer: Collectively, our data confirmed that the activation of autophagy, which occurs as a consequence of Tam treatment, contributes to Tam resistance of ER+ breast cancer cells by relocating inside the lysosomal lumen the protective factors capable of restraining the drug-induced lysosomal damage.